



Express Mail Label No. EL935284642US
Date of Deposit: April 16, 2002

ATTORNEY DOCKET NO. B00192/70019 (ERP/MXA)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Van Broeckhoven et al.
Serial No: 09/581,500
Confirmation No.: 9967
Filed: November 14, 2000
For: MOOD DISORDER GENE
Examiner: Diana B. Johannsen
Art Unit: 1655

U.S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, VA 22202

Sir:

STATEMENT PURSUANT TO 37 CFR 1.821(f) AND 37 CFR 1.825 (a) and (b)

This is responsive to the communication from the Examiner mailed on December 8, 1999 (notice to comply with sequence listing requirements). This statement is made pursuant to 37 CFR 1.821 (f), and 37 CFR 1.825 (a) and (b). Applicants submit herewith a substitute copy of the written sequence listing and a computer readable diskette to comply with the sequence requirements. The amendments to the sequence listing relate only to eliminating the errors detected in the previously submitted sequence listing. No new matter has been added.

Applicants' attorney states that the information recorded in computer readable form is identical to the written sequence listing and that neither the computer readable form nor the written sequence listing contain new matter.

Respectfully submitted,

Van Broeckhoven, et al., Applicants

Elizabeth R. Plumer
Elizabeth R. Plumer, Reg. No. 36,637
WOLF, GREENFIELD & SACKS, P.C.
600 Atlantic Avenue
Boston, Massachusetts 02210-2211
(617) 720-3500

Attorney Docket No. B00192/70019 (ERP/MXA)

Date: April 16, 2002

X04/18/02

RECEIVED
APR 19 2002
TECH CENTER 1600/2900

APR 16 2002

Application No.: 09/581,500

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).

2. This application does not contain, as a separate part of the disclosure on paper copy, an "Sequence Listing" as required by 37 C.F.R. 1.821(c).

3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).

4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."

5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).

6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).

7. Other: _____

Applicant Must Provide:

An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".

An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.

A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support

Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR REPLY